Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection.

A calcineurin-inhibitor- and steroid-free regimen pairing the CD154 blocker dazodalibep with belatacept as the only maintenance immunosuppression was safe and well tolerated in new kidney transplant recipients, but a quarter still developed treated acute rejection, so it did not meet its efficacy goal.